|
38 |
FDA issues draft guidance on post-warning letter meetings under GDUFA III
|
sureAssist |
2024-12-26 |
509 |
|
37 |
5 Best Practices For Responding To FDA Form 483 Inspection Observations
|
sureAssist |
2024-12-26 |
607 |
|
36 |
Cleanrooms: solving the mystery of recurring low level contamination
|
sureAssist |
2024-12-26 |
461 |
|
35 |
The possible Impact of Artificial Intelligence on the Role of the Qualified Person
|
sureAssist |
2024-12-26 |
491 |
|
34 |
Preparing A framework For Artificial Intelligence And Machine Learning Validation: A 3-Step Approach
|
sureAssist |
2024-12-26 |
638 |
|
33 |
CGMP Requirements For Automated Facility Monitoring Systems
|
sureAssist |
2024-12-26 |
523 |
|
32 |
RTU vs concentrate disinfectants: efficiency as a factor in selection
|
sureAssist |
2024-12-26 |
537 |
|
31 |
EMA phases out extraordinary COVID-19 regulatory flexibilities
|
sureAssist |
2024-12-26 |
504 |
|
30 |
6 Ways To Achieve Manufacturing Audit And Inspection Readiness
|
sureAssist |
2024-12-26 |
536 |
|
29 |
FDA issues draft guidance on reporting manufacturing changes for gene therapies
|
sureAssist |
2024-12-26 |
537 |
